We would like to thank Vera-Badillo et al¹ for their comments on our article, “Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.”² Their letter raises interesting questions about the overall state of oncology drug development, particularly targeted therapies.

中文翻译：

---

回复FE Vera-Badillo等。

我们要感谢Vera-Badillo等人¹对我们的文章“铂类药物和抗程序性死亡1 /程序性死亡配体1治疗后恩妥单抗Vedotin在尿路上皮癌中的关键试验”的评论。²他们的信提出了有关肿瘤学药物开发总体状况的有趣问题，特别是针对性疗法。